ArticleJournal of the Society for Cardiovascular Angiography & Interventions2026
Pharmacokinetic Profile of Everolimus Eluted From the Esprit BTK Scaffold: A LIFE-BTK Pharmacokinetics Substudy.
Article in Journal of the Society for Cardiovascular Angiography & Interventions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in targeted and cellular therapies for relapsed/refractory mantle cell lymphoma: immunotherapeutic strategies and challenges.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The most severe manifestation of peripheral artery disease, chronic limb-threatening ischemia, is associated with limited treatment options for below-the-knee (BTK) arteries. The Esprit BTK everolimus-eluting resorbable scaffold system (Abbott), now approved by the U.S. Food and Drug Administration for the treatment of infrapopliteal lesions in patients with chronic limb-threatening ischemia, was evaluated in the LIFE-BTK randomized controlled trial. LIFE-BTK included a nonrandomized substudy evaluating the pharmacokinetic (PK) profile of everolimus eluted from the scaffold. Methods: The PK substudy enrolled 9 subjects across 2 treatment groups (with or without drug-coated balloon use for inflow lesion and/or nontarget lesion treatment). Blood concentration-time profiles and PK parameters were determined at multiple time points and compared with prior PK results from the Absorb bioresorbable vascular scaffold. Results: The number of implanted scaffolds averaged 6.6 ± 0.9, with a total length ranging from 180 to 256 mm and an everolimus dose ranging from 1397 to 2074 μg per subject. The last time point at which everolimus could be quantified ranged from 168 to 720 hours, and in most cases, the blood concentrations dropped below the lower limit of quantification (0.1 ng/mL) before 720 hours. Peak blood everolimus levels were followed by a biexponential decline, with terminal phase half-life ranging from 65.6 to 211.2 hours. A regression analysis using dose-normalized maximum blood everolimus concentration and area under the blood concentration-time curve confirmed similar everolimus exposure across the treatment groups. Conclusions: The present substudy assessed the PK of everolimus delivered by Esprit BTK in the planned treatment of narrowed infrapopliteal lesions. This study confirms that the PK profile of everolimus eluted from the Esprit BTK scaffold results in limited systemic exposure and is considered to be safe and well tolerated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.